Unicycive Therapeutics announced positive results from a Phase 2 trial of its investigational phosphate binder, oxylanthanum carbonate (OLC), for chronic kidney disease (CKD) patients on dialysis. The study demonstrated that OLC effectively controlled serum phosphate levels in over 90% of patients with a low pill burden, typically three or fewer tablets daily. The drug was also found to be well-tolerated, with mostly gastrointestinal side effects reported.
This news holds substantial promise for dialysis patients struggling with hyperphosphatemia, a serious condition linked to increased mortality and hospitalization. Current treatment options often necessitate a high pill burden, impacting patient adherence. OLC’s efficacy with fewer pills addresses this critical unmet need, potentially leading to improved patient outcomes and quality of life.
The Phase 2 trial involved 86 patients, of whom only 59% initially had controlled phosphate levels. OLC significantly improved this, achieving control in over 90% of participants. Importantly, pharmacokinetic data confirmed minimal systemic absorption of lanthanum, suggesting a favorable safety profile. This data completes the clinical evidence required for the New Drug Application (NDA) submitted to the FDA. Unicycive is actively working with the FDA to resolve manufacturing questions and expedite OLC’s availability to patients.
The positive clinical results and low pill burden position OLC as a potentially best-in-class phosphate binder. Its approval could significantly improve the standard of care for hyperphosphatemia, offering patients a more convenient and effective treatment option. This development could benefit Unicycive by securing market share in a large patient population currently underserved by existing therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
